A study of the correlation of non-motor symptoms of Parkinson’s disease and Parkinson plus syndrome with duration of the disease

Verma V.K¹, Uraiya D², Kumar A³, Tripathi N⁴, Dhoan P⁵

¹Dr. Verma VK, Assistant Professor, ²Dr. Uraiya D Associate Professor, ³Dr. Kumar A, Associate Professor, ⁴Dr. Tripathi N, Assistant Professor, ⁵Dr. Dhoan P, Assistant Professor, all authors are affiliated with Department of Medicine, Hind Institute of Medical Science, Safidabad, Barabanki, UP, India.

Address for Correspondence: Dr Dharmendra Uraiya, Associate Professor, Department of Medicine, Hind Institute of Medical Science, Safidabad, Barabanki, UP, India, Email: drdharm@gmail.com

Abstract

Introduction: Depression is common in PD, occurring in up to one-half of the patients. Anxiety disorders may be as common as depression and the two are frequently co-existent. Parkinson plus syndrome (PPS) is a group of sporadic, neurodegenerative diseases of the central nervous system, less common and usually more severe than Parkinson’s disease. They are characterised by relatively rapid disease progression and the presence of features that are atypical for PD, such as early postural instability and dementia, severe autonomic failure, or pyramidal and cerebellar signs. Material and Methods: The study was conducted to assess the effect of duration in non-motor dysfunction in 60 patients with Parkinsonism including idiopathic Parkinson’s disease and Parkinson plus syndrome who attended either the outdoor services, or were admitted in the Neurology ward of our tertiary care centre, PGIMER & Dr. RML Hospital, New Delhi, India. Results: PD patients had no correlation between cognition and duration of disease (p=0.079 with MMSE and p=0.145 with SCOPA COG) but had significant correlation between depression, sleep problems, pain and autonomic dysfunction with duration of disease (p=0.027, 0.008, 0.010 and 0.042 respectively). Conclusion: Early recognition and diagnosis of PD and PPS is important as treatment may improve quality of life in patients. Co-existence of non-motor dysfunctions in the disease significantly adds to the burden of disease and affects the quality of life.

Keywords: Parkinson’s disease, Parkinson plus syndrome, Non motor symptoms, Neuropsychiatric symptoms.

Introduction

Parkinson’s disease (PD) is a common neurodegenerative disorder second only to Alzheimer’s disease [1]. The cardinal clinical features of PD include asymmetric onset bradykinesia, rigidity and rest tremor [2]. The peak age of onset of PD is in the early 60s (range 35-85 years), and the course of illness ranges from 10 to 25 years [3].

The Parkinson’s disease result from the loss of dopaminergic neurons in substantia nigra pars compacta [4]. Among the subjects with clinical features of Parkinsonism, approximately 80-85% have PD and the rest are Parkinson Plus Syndrome and secondary Parkinsonism [5]. Disorders of mood and affect, though receiving less attention than motor aspects of the disease, have long been recognized as a part of PD. Depression is common in PD, occurring in up to one-half of the patients. Anxiety disorders may be as common as depression [6, 7] and the two are frequently co-existent. Apathy, may overlap, but is usually distinct from depression.

In addition, suicidal ideations, hallucinations, and delusions may occur [8, 9] When PD patients are carefully questioned, it becomes evident that fatigue, sleepiness, and sleep disturbances are major problems independent of any medication and motor disability.

Parkinson plus syndrome (PPS) is a group of sporadic, neurodegenerative diseases of the central
nervous system, less common and usually more severe than Parkinson’s disease. They are characterised by relatively rapid disease progression and the presence of features that are atypical for PD, such as early postural instability and dementia, severe autonomic failure, or pyramidal and cerebellar signs. Survival time is shorter and more complications occur in earlier stages and with higher degree of severity than in PD [10].

We conducted the present study to assess the non-motor dysfunction in idiopathic PD and PPS, and to find if these symptoms associated with the duration of the disease.

Material and Methods

Study design: It was a cross-sectional study.

Study population: The study was conducted to assess the effect of duration in non-motor dysfunction in 60 patients with Parkinsonism including idiopathic Parkinson’s disease and Parkinson plus syndrome who attended either the outdoor services, or were admitted in the Neurology ward of our tertiary care centre, PGIMER & Dr. RML Hospital, New Delhi, India.

Inclusion criteria: Patients with Parkinsonism disease.

Exclusion Criteria
1. Systemic conditions known to be associated with autonomic dysfunction including diabetes, chronic alcoholism, chronic renal failure, chronic liver disease.
2. Patients with essential tremor
3. Patients with secondary parkinsonism
4. Severe cognitive dysfunction such that the relevant questionnaires for assessment cannot be undertaken by the patient
5. Refusal to give consent for study

Results

In our study, out of 40 patients with Parkinson’s disease, twenty-five (62.50%) were males and 15 (37.50%) were females with mean age of 55.02 (SD ±13.56) years as shown in table 1. Among patients with MSA, six (66.70%) were male and 3 (33.33%) were female with mean age of 62.00 (SD ±11.38) years. Among patients with PSP, four (50.00%) were male and 4 (50.00%) were female with mean age of 62.37 (SD ±10.25) years while all the three patients with DLB were male having mean age of 65.33 (SD ±12.34) years.
Table-1: Clinical profile of sample population.

| Age at onset [Frequency (%)] | PD (n=40) | DLB (n=3) | MSA (n=9) | PSP (n=8) | PPS (n=20) | p value (PD vs PPS) |
|-----------------------------|-----------|-----------|-----------|-----------|------------|---------------------|
| ≤40 Yrs                     | 5 (12.50) | 0 (0%)    | 0 (0%)    | 0 (0%)    | 0 (0%)     |                     |
| >40 Yrs                     | 35 (87.50%) | 3 (100%) | 9 (100%) | 8 (100%) | 20 (100%) |                     |
| Duration of Disease [Mean ± SD] | 2.09 ± 1.82 | 3.17 ± 0.29 | 2.67 ± 1.52 | 1.90 ± 1.11 | 2.43 ± 1.29 | 0.455 |
| <2 yrs                      | 19 (47.5%) | 0 (0%)    | 4 (44.4%) | 3 (37.5%) | 7 (35%)    |                     |
| 2 - 5 yrs                   | 19 (47.5%) | 3 (100%)  | 5 (55.6%) | 5 (62.5%) | 13 (65%)   |                     |
| >5 yrs                      | 2 (5%)    | 0 (0%)    | 0 (0%)    | 0 (0%)    | 0 (0%)     |                     |
| UPDRS (III)                 | 22.10 ± 5.83 | 27.00 ± 3.00 | 22.88 ± 9.78 | 26.00 ± 4.50 | 24.75 ± 7.20 | 0.131 |

PD patients had mean disease duration of 2.09(SD ±1.82) years. Thirty-eight (95%) PD patients had less than 5 years of disease duration and only 2 (5%) subjects had disease duration of more than 5 years. The mean duration of disease in MSA patients was 2.67 (SD ±1.52) years with 4 (44.44%) and 5 (55.56%) subjects having <2 years and 2-5 years duration of disease respectively. Patients with PSP had mean disease duration of 1.90 (SD ±1.11) years with 3 (37.50%) and 5 (62.50%) subjects having <2 years and 2-5 years duration of disease respectively. Amongst DLB patients, the mean duration of illness was 3.17(SD ±0.29) years with all the subjects in 2-5 years disease duration range. The mean UPDRS-III score of PD and Parkinson plus syndrome patients was 22.10 (SD ±5.83) and 24.75(SD ±7.20) respectively (Table No. 1).

Table No.-2: Relation of non motor symptoms scales score with duration of disease in Parkinson’s disease

| Name of scale | <2 yrs (n=19) Mean (SD) | 2 - 5 yrs (n=19) Mean (SD) | >5 yrs (n=2) Mean (SD) | (n=40) Mean (SD) | P value |
|---------------|-------------------------|-----------------------------|------------------------|------------------|--------|
| MMSE          | 25.68±3.667             | 23.68(±5.121)               | 30.00±0.0              | 24.95(±4.546)    | 0.079  |
| SCOPA-COG     | 23.84(±5.263)           | 22.84(±5.550)               | 29.50(±3.536)          | 23.65(±5.423)    | 0.145  |
| DBI-II        | 7.95(±8.784)            | 15.16(±8.952)               | 15.50(±13.43)          | 11.75(±9.521)    | 0.027  |
| PDSS          | 132.16(±35.059)         | 122.53(±20.034)             | 108.50(±6.364)         | 126.40(±28.169)  | 0.008  |
| PAIN          | 3.11(±2.079)            | 5.58(±2.714)                | 6.00(±0.00)            | 4.42(±2.650)     | 0.010  |
| SCOPA-AUT     | 11.05 ± 6.51            | 15.42 ± 5.20                | 16.50 ± 0.71           | 13.40 ± 6.10     | 0.042  |

PD patients had no correlation between cognition and duration of disease (p=0.079 with MMSE and p=0.145 with SCOPA COG) but had significant correlation between depression, sleep problems, pain and autonomic dysfunction with duration of disease (p=0.027, 0.008, 0.010 and 0.042 respectively) (Table no. 2).

Table No.-3: Relation of non motor symptoms scales score with duration of disease in Parkinson plus Syndrome.

| Name of Scale | Duration of disease | p value |
|---------------|---------------------|--------|
|               | <2 Yrs (n=7)        | 2-5 Yrs (n=13) | >5 Yrs (n=0) |
| MMSE          | 24.57 ± 4.58        | 20.69 ± 6.81 | 0.0 ± 0.0    | 0.176  |
| SCOPA-COG     | 25.57 ± 5.91        | 22.69 ± 5.14 | 0.0 ± 0.0    | 0.176  |
| BDI-II        | 5.29 ± 4.68         | 11.62 ± 9.41 | 0.0 ± 0.0    | 0.163  |
| PDSS          | 138.00 ± 9.68       | 132.31 ± 12.21 | 0.0 ± 0.0    | 0.302  |
| VAS           | 2.43 ± 2.15         | 2.46 ± 1.94  | 0.0 ± 0.0    | 0.799  |
| SCOPA-AUT     | 13.71 ± 7.04        | 17.77 ± 4.93 | 0.0 ± 0.0    | 0.190  |
Parkinson plus Syndrome patients had correlation between cognition impairment, depression, sleep problems, pain and autonomic dysfunction with duration of disease but not statistically significant (p=0.176 with MMSE, p=0.176 with SCOPA-COG, p=0.302 with PDSS, P=0.799 with VAS and p=0.190 with SCOPA-AUT) (Table No. 3).

**Discussion**

The mean duration of illness was 2.09 (SD ± 1.82) years for subjects with PD and 2.43 (SD± 1.29) years for subjects with PPS. Most of patients of PPS had moderate to severe disease (19 out of 20 patients) while around 60% (24 patients) of PD were of the similar severity.

The mean UPDRS-III score of PPS patients was higher than that of PD patients (Mean ± SD: 24.75 ± 7.20) than PD (Mean ± SD: 22.10 ± 5.83).

Using MMSE, cognitive impairment was observed in 12 (30%) cases of PD in which 9 (22.50%) had mild and 3 (7.50%) had moderate cognitive impairment. On the SCOPA-COG scale, cognitive impairment was observed in 9 (22.5%) patients. We did not find any significant correlation between cognitive impairment and duration of disease in PD.

(MMSE P value=0.079 with duration and P value =0.925 with Modified H & Y and 0.791 with UPDRS-III, SCOPA. COG P value =0.145 with duration and P value =0.978 with Modified H & Y and P value =0.785 with UPDRS-III.

Earlier estimates of prevalence of dementia in PD have been highly variable, ranging from 20% to 81% [15]. This might be due to different assessment techniques and different study populations.

Depression was observed in all the PD patients using BDI-II. There was significant correlation of depression with duration (p=0.027) of illness. Statistically significant correlation was found between depression and duration of disease when assessed by UPDRS-III (p= 0.003).

Our finding is in concordance with previous literature. Reijnders JSAM et al. and Tan LCS reported major depressive disorder in 17%, minor depressive disorder in 22%, and dysthymia in 13% of their PD patients. They observed clinically significant depressive symptoms in 35% of PD patients [16, 17]

The sleep problems significantly correlated with duration and severity of disease in PD (p=0.008, p=0.015 and p<0.001 correlation with duration, Modified H & Y and UPDRS-III respectively). Using NPI, 62.5% patients had night behaviours problems with sleep fragmentation, early awakening and excessive naps during day time.

Our findings were similar to that reported by other authors. Tandberg Ert al. reported sleep problems in 60% [18]. Behari M et al reported sleep problems in 42% in which 32% insomnia, 32% nightmares and 15% excessive day time sleepiness [19].

In PPS patients, 45% reported having pain. In individual groups, pain was present in 44.44%, 50% and 33.33% of MSA, PSP and DLB patients respectively. This finding is similar to other studies. Tison F et al. found that 47% had pain in MSA [20]. In our study PPS patients had no statistically significant correlation of pain with duration (p=0.799) and severity (p=0.698 with Modified H & Y and 0.105 with UPDRS) of disease.

In PD, autonomic dysfunctions were significantly increased with duration and severity of disease (p=0.042 with duration and p<0.001 with mod. H & Y staging and UPDRS-III). The autonomic dysfunctions in PD patients were similar to previous studies. Visser Visser M. et al. reported that the prevalence of autonomic disturbances ranged between 14% and 80%, and these symptoms were better evaluated with the SCOPA-AUT scale [21].

**Conclusion**

Non-motor symptoms are a frequent cause of hospitalisation which can increase the cost of care of patients with PD by four times. Early recognition and diagnosis of PD and PPS is important as treatment may improve quality of life in patients. Co-existence of non-motor dysfunctions in the disease significantly adds to the burden of disease and affects the quality of life.
Funding: Nil, Conflict of interest: None
Permission of IRB: Yes

References

1. Przedborski S. Etiology and pathogenesis of PD. In: Jankovic J, Tolosa E, eds. PD and Movement Disorders 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2007; 77-92.

2. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord. 2007 Oct 15;22(13):1901-11.

3. Delong MR, Juncos JL. PD and other extrapyramidal movement disorders. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., eds. Harrison's principles of internal medicine 17th ed. New York (NY): The McGraw-Hill Companies 2008; 25:49-59.

4. Jankovic J, Shannon KM. Movement Disorders. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, eds. Neurology in clinical practice 5th ed. Philadelphia:Butterworth-Heinemann, Elsevier; 2008; 2081-122.

5. Mitra K, Gangopadhyaya PK, Das SK. Parkinsonism plus syndrome--a review. Neurol India. 2003 Jun;51(2):183-8.

6. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1996 Fall;8(4):383-92.

7. Walsh K, Bennett G. Parkinson's disease and anxiety. Postgrad Med J. 2001 Feb; 77 (904): 89-93.

8. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med. 1987 Nov;17(4): 899-904.

9. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Ponct M, Chérif AA. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology. 2002 Aug 13; 59 (3): 408-13.

10. Litvan I. Update of atypical Parkinsonian disorders. Curr Opin Neurol. 2007 Aug; 20 (4): 434-7.

11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. JNPN 1992; 55:181-184.

12. Steer RA, Clark DA, Beck AT, Ranieri WF. Common and specific dimensions of self-reported anxiety and depression: the BDI-II versus the BDI-IA. Behav Res Ther. 1999 Feb;37(2):183-90.

13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–2314.

14. Schenkman ML, Clark K, Xie T, Kuchibhatla M, Shinberg M, Ray L. Spinal movement and performance of a standing reach task in participants with and without Parkinson disease. Phys Ther. 2001 Aug; 81(8):1400-11.

15. Bassett SS. Cognitive impairment in Parkinson’s disease. Clinical Focus Primary Psychiatry 2005; 12:50-55.

16. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008 Jan 30;23(2):183-9; quiz 313.

17. Tan LC. Mood disorders in Parkinson's disease. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1: S74-6. doi: 10. 1016 /S1353-8020 (11) 700 24-4.

18. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord. 1998 Nov; 13(6):895-9.

19. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord. 2002 Jul;17 (4):775-81.
20. Tison F, Wenning GK, Volonte MA, Poewe WR, Henry P, Quinn NP. Pain in multiple system atrophy. J Neurol. 1996 Feb;243(2):153-6.

21. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord. 2004 Nov;19(11):1306-12.

How to cite this article?
Verma V.K, Uraiya D, Kumar A, Tripathi N, Dhoan P. A study of the correlation of non-motor symptoms of Parkinson’s disease and Parkinson plus syndrome with duration of the disease. Int J Med Res Rev 2017;5(08):814-819.doi:10.17511/ijmrr. 2017.i08.07.